Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In November 2021, in partnership with SIIPL, the Company received EUA from the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Pengawas Obat dan Makanan, following the August 2021 regulatory submission made by SIIPL with support from the Company. EUA was granted for the Company's recombinant nanoparticle protein-based vaccine with its Matrix-MTM adjuvant, which will be manufactured and marketed in Indonesia by SIIPL under the brand name COVOVAXTM. Indonesia contracted with SIIPL for the purchase of 50 million doses of COVOVAXTM. In November 2021, the Company completed the rolling submission of all modules required by the European Medicines Agency ("EMA") to support final regulatory review. The final step to complete the application in the European Union will be an invitation from EMA to file for conditional marketing authorization. In October and November 2021, the Company completed rolling regulatory submissions in key markets for NVX-CoV2373. The Company filed for conditional marketing authorization with the United Kingdom Medicines and Healthcare products Regulatory Agency, leveraging its manufacturing partnership with SIIPL. Additionally, the Company filed for provisional approval with Australia’s Therapeutic Goods Administration, authorization with Health Canada, provisional approval with New Zealand Medicines and Medical Devices Authority and the WHO for EUL. In October 2021, the Company entered into a supply agreement with SIIPL and Serum Life Sciences Limited. ("SLS"), an affiliate of SIIPL, for the manufacture of NVX-CoV2373. In October 2021, the Company also entered into a contract development manufacture agreement with SLS, where SLS will manufacture and supply finished vaccine product to the Company using antigen drug substance and Matrix-M™ adjuvant supplied by the Company. In October 2021, the Company entered into a CMO agreement with Mabion S.A. (“Mabion”) for the large-scale manufacturing of NVX-CoV2373 through 2026 at the Mabion facility located near Warsaw, Poland. In October 2021, the Company entered into a lease for approximately 63,000 square feet of space for premises located in Germantown, MD. The Company intends to use the premises for manufacturing, research and development and offices. The term of the lease is approximately eight years with options to extend the lease. The lease provides for an annual base rent of $1.9 million that is subject to future rent increases, and obligates the Company to pay building operating costs.